Member Info for neilrich3

The difference between capacity and tests conducted within pillar 1, is an interesting question! At first glance this disparity concerned me, however how do they measure capacity for the Q16 and Q32?

Within the UK Government Lighthouse labs I'd imagine that they work around the clock 24/7.

Within Pillar 1 it's a different story, the Q32/Q16 shall not be in use around the clock, there shall be peaks and troughs in the demand for testing, for instance used less overnight and at times the machines operating only a third full.

I feel that this explains the disparity between testing capacity and tests conducted. It's not simply a case of 30 tests every hour (24/7) which I'd imagine is how they calculate capacity.

Therefore more than likely that December was not invoiced until 4th Jan, or perhaps later.

It was 26 Oct when Pillar one testing capacity ramped up, therefore possible that only the one full month invoiced for 2020.

Also, capacity is likely to be measured upon Q32/Q16 being utilised around the clock (24/7), the reality is likely to be heavy utilisation a certain periods of the day within the hospital environment, other times of the day, such as overnight, the machines are not being used and/or only at 50% capacity when they are.

Looking at the pillar one data, it would appear that the Q16/Q32 is still being rolled out, this coming week should see pillar one capacity exceed 200,000 tests a day for the first time. Pillar one tests conducted have also been increasing, especially in recent weeks, although there remains much unused capacity.

I feel that the DHSC phase 1 contract shall be extended, having spent a number of months increasing the pillar one capacity, a u turn in the middle of a pandemic would see the capacity fall by more than half, that would not be wise move from the DHSC.

My thinking is that phase 1 shall be extended, phase 2 is less certain, more likely a renegotiated phase 2 I feel given the level of unused capacity at present. Might a renegotiated phase 2 include schools as opposed to care homes?

Also, I feel that testing for COVID within the hospital environment shall continue well beyond 2021.

Not likely that DHSC shall kick NCYT out of bed in the midst of the pandemic.

Also, let's not forget all the exciting new products coming during 2021. Time to remain focused upon the job at hand, which is what the board appear to be doing with an ability to innovate and resolve issues quickly.

Maddog....Please remind me, what was the target figure for the number of tests per week under phase 1 of the contract?

@rottenpig. Sorry, who was expecting £1 billion revenue? The numbers were bang on the consensus , in my opinion.

Rotten pig is suggesting that NCYT are selling their PCR tests at £90 a pop....good luck mate!

Give me strength....Primerdesign are more than likely selling there tests at between £7 and £15 a test. Like I said, clearly the little Piggy has done some great research!! lol

Good to see that the little piggy has done his research....100? That's strange when you considered that they employed 130 new people in 2020....like investing, I guess not very good at maths either.

Also, end of the day.....we've already supplied products to "over 130 countries globally" and yet everyone (including myself) is getting hung up over DHSC phase 2.

Unlike Greggs (P/E 48) NCYT has a truly global market and next week a contract could easily be signed with another Government that blows DHSC out of the water and that's before potential new products arrive that we already know are in the pipeline.

Surly difficult for DHSC to justify a U turn in the middle of a pandemic, having already spent a considerable amount of money, clearly there has been issues, however these appear to have been resolved with the introduction of ProMate, either way hospitals shall continue to test patients for COVID and that'll go well beyond 2021. What's the alternative? Introducing new equipment from a competitor would not be without considerable risk.

End of the day....there are few companies better placed than NCYT, for instance £100 million sitting in the bank.

At the AGM 29/09/2020 (the end of Q3) the CEO reported that 'Full year revenues are expected to now significantly exceed €150m and EBITDA significantly exceed €100m'.

He was not wrong and he did not lie or mislead.

I'm not convinced that the North did....think that the South was first.

Also, I'd imagine not just NHS North, almost certainly South too.

Totally agree, the priority is to build the company, not to sort out the PR. Look at the two recent appointments:
1) Chief Corporate Development Officer;
2) Chief Commercial Officer.

Siemens Healthineers, a German medical technology company, named the new Global Director of Marketing, Sales and Communications in the Guillermo Raimondo Laboratory Diagnostic Segment. Since 1994, the professional has developed into an exit carrier as responsible for strategic planning, marketing and global angiography sales.

President of the Latin American Health Bargaining Party, leading a group of more than 1,700 people. From the 16th of July the areas mentioned in all the world reported to him, who should define the sales strategy, ensure the provision of resources and promote the measures to guarantee global revenue.

https://cl.linkedin.com/in/guillermo-raimondo

Wow! Liking his CV, hopefully this appointment shall pay dividends.

The appointment of a Chief Commercial Officer during January demonstrates their ambition, this company has a truly global market and they are after a share.

Novacyt has also appointed Guillermo Raimondo to the newly formed, non-Board role of Chief Commercial Officer to lead the Company’s global commercial operations. Previously, Guillermo had a successful career at Siemens Healthineers where his last two roles were as Regional President and more recently Executive Vice President Global Marketing & Sales, responsible for $4 billion of global revenues.

Also, it was only 44 calendar days between the CEO's share purchase and the end of the financial year, there's stuff in the pipeline, things to come during 2021 that we know nothing about. Time to take the medium to long term view, I'm happy to be holding shares in company that has a global market, circa £100 million cash in the bank, zero debt and trades on a PE of <4!! Also, not as if BlackRock took a wild punt on NCYT....they did their research.

Please can someone confirm the EPS based upon Today's figures? Many thanks.